Rhythm Pharmaceuticals, Inc. (RYTM)
NASDAQ: RYTM · Real-Time Price · USD
93.44
+0.87 (0.94%)
At close: Nov 2, 2026, 4:00 PM EST
93.46
+0.02 (0.02%)
After-hours: Nov 2, 2026, 7:32 PM EST
Rhythm Pharmaceuticals Employees
Rhythm Pharmaceuticals had 414 employees as of December 31, 2025. The number of employees increased by 131 or 46.29% compared to the previous year. That makes Rhythm Pharmaceuticals the 21,478th largest employer in the world and 2,826th in the United States.
Employees
414
Change (1Y)
131
Growth (1Y)
46.29%
Revenue / Employee
$579,512
Profits / Employee
-$507,783
Market Cap
6.43B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 414 | 131 | 46.29% |
| Dec 31, 2024 | 283 | 57 | 25.22% |
| Dec 31, 2023 | 226 | 49 | 27.68% |
| Dec 31, 2022 | 177 | 37 | 26.43% |
| Dec 31, 2021 | 140 | 50 | 55.56% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Ionis Pharmaceuticals | 1,480 |
| Axsome Therapeutics | 1,346 |
| Mirum Pharmaceuticals | 433 |
| Immunovant | 315 |
| Cogent Biosciences | 258 |
| CG Oncology | 142 |
| Kodiak Sciences | 141 |
| Oruka Therapeutics | 68 |
RYTM News
- 12 days ago - Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026 - GlobeNewsWire
- 18 days ago - Rhythm Pharmaceuticals initiated with an Outperform at William Blair - TheFly
- 18 days ago - JPMorgan trims Rhythm Pharmaceuticals target, adds to Analyst Focus List - TheFly
- 20 days ago - Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity - GlobeNewsWire
- 21 days ago - Rhythm Pharmaceuticals price target raised to $130 from $105 at H.C. Wainwright - TheFly
- 24 days ago - Rhythm Pharmaceuticals price target raised to $150 from $149 at BofA - TheFly
- 25 days ago - Rhythm Pharmaceuticals price target raised to $159 from $155 at RBC Capital - TheFly
- 5 weeks ago - Rhythm announces Health Canada has approved IMCIVREE - TheFly